

## Solomon Islands Support for Pentavalent Vaccine

### This Decision Letter sets out the Programme Terms

<b>1. Country:</b> Solomon Islands				
<b>2. Grant number:</b> 1720-SLB-04a-X / 08-SLB-08a-Y				
<b>3. Date of Decision Letter:</b> 12 March 2019				
<b>4. Date of the Partnership Framework Agreement (PFA):</b> 29 April 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
<b>8. Programme duration<sup>1</sup>:</b> 2008 -2020				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the PFA, if applicable)				
	<b>2008-2018</b>	<b>2019</b>	<b>2020</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	1,192,504 <sup>3</sup>	14,000	11,000	\$1,217,504
<b>10. Vaccine introduction grant (in US\$):</b> \$100,000 disbursed 5 February 2008				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the PFA, if applicable) <sup>4</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2008-2018</b>	<b>2019</b>		
Number of Pentavalent vaccines doses		12,400		
Annual Amounts (US\$)	1,192,504 <sup>5</sup>	14,000		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>13. Self-procurement:</b> Not applicable.				

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p><b>14. Co-financing obligations:</b> Reference code: 1720-SLB-04a-X-C</p> <p>According to the co-financing policy, the Country falls within the group Accelerated Transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>																							
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2019</th> <th>2020</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>57,100</td> <td>52,900</td> </tr> <tr> <td>Number of AD syringes</td> <td>60,100</td> <td>55,400</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>700</td> <td>625</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>59,872</td> <td>55,443</td> </tr> <tr> <td>Total co-financing payments (US\$) (incl. freight)</td> <td>67,000</td> <td>62,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	2019	2020	Number of vaccine doses	57,100	52,900	Number of AD syringes	60,100	55,400	Number of re-constitution syringes			Number of safety boxes	700	625	Value of vaccine doses (US\$)	59,872	55,443	Total co-financing payments (US\$) (incl. freight)	67,000	62,000		
Type of supplies to be purchased with Country funds in each year	2019	2020																					
Number of vaccine doses	57,100	52,900																					
Number of AD syringes	60,100	55,400																					
Number of re-constitution syringes																							
Number of safety boxes	700	625																					
Value of vaccine doses (US\$)	59,872	55,443																					
Total co-financing payments (US\$) (incl. freight)	67,000	62,000																					
<p><b>15. Additional reporting requirements:</b> Not applicable</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>				Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>															
	Due dates																						
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>																						
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>																						
<p><b>16. Financial clarifications*:</b></p> <p>Solomon Islands must continue to meet Gavi financial management requirements, including the submission financial and audit reports and adherence to the country's Grant Management Requirements.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>																							
<p><b>17. Other conditions:</b> Not applicable</p>																							

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
12 March 2019